Get alerts

Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.

THNR · Amplify Weight Loss Drug & Treatment ETF

Amplify · Themes desk

Open the live card on ETFIQ

THNR has no public holdings filing captured yet. Over the year to Sep 4, 2026 the fund returned +18.1% with distributions reinvested against +20.0% for the S&P 500, so a holder was behind by 1.9 pts.

THNR (Amplify Weight Loss Drug & Treatment ETF), themes desk fields as of Sep 4, 2026. Source: ETFIQ.
Theme (ETFIQ, editorial)Healthcare innovation and GLP-1
LaunchedMay 21, 2024
3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ)+11.1% / +4.7% / +6.4 pts / +9.0 pts
6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ)+9.5% / +15.2% / −5.7 pts / −10.7 pts
1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ)+18.1% / +20.0% / −1.9 pts / −7.5 pts
since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ)+9.1% / +48.9% / −39.7 pts / −50.5 pts
Below its all-time high (ETFIQ)−3.2%

Questions people ask

Has THNR beaten the S&P 500?
Over the year to Sep 4, 2026 THNR returned +18.1% with distributions reinvested, against +20.0% for the S&P 500, so it finished behind the index by 1.9 points.

Where these figures came from

ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.

Funds near this one

Cite this page. ETFIQ, THNR on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/THNR.html Free to use with attribution; the underlying files are at Open data.

ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk